April 18 (Reuters) - Bristol-Myers Squibb Co BMY.N:
U.S. FOOD AND DRUG ADMINISTRATION UPDATES CAMZYOS® (MAVACAMTEN) LABEL TO REDUCE ECHOCARDIOGRAPHY MONITORING REQUIREMENTS AND CONTRAINDICATIONS
Source text: ID:nBw5rr4Q6a
Further company coverage: BMY.N
((reuters.briefs@thomsonreuters.com;))